A Phase 2 interventional study of Buprenorphine in Opioid-Related Disorders, sponsored by University of Vermont. Completed at 1 site in United States. Open to participants aged 22 Years to 51 Years. Per ClinicalTrials.gov, last updated 2016-05-06.
Sponsored by University of Vermont · Phase 2, Interventional, and Treatment
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
Browse Opioid-Related Disorders studies →University of Vermont is the lead sponsor of 215 studies on the registry; 28 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Please contact site for information.
Drug use
Opioid withdrawal
Opioid agonist effects
Dose identification
Pupil diameter
This study is completed, as verified in Apr 1994. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Vermont